We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+3.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.91B
AUM Growth
+$61.2M
(+2.1%)
Cap. Flow
+$64.4M
Cap. Flow
% of AUM
2.22%
Top 10 Holdings %
Top 10 Hldgs %
30.43%
Holding
226
New
26
Increased
31
Reduced
48
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$41M |
| 2 |
Abbott
ABT
|
+$37M |
| 3 |
Moderna
MRNA
|
+$32.5M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$29.2M |
| 5 |
Gilead Sciences
GILD
|
+$26.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$60.5M |
| 2 |
Becton Dickinson
BDX
|
+$22.1M |
| 3 |
Humana
HUM
|
+$18.1M |
| 4 |
Bio-Techne
TECH
|
+$16.1M |
| 5 |
NovoCure
NVCR
|
+$15.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.75% |
| 2 | Real Estate | 2.99% |
| 3 | Industrials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Replimune Group
REPL
$941M
| $6.68M | 0.23% |
+219,060
| New | +$8.2M |
|
102
Agilent Technologies
A
$39.1B
| $6.68M | 0.23% |
52,525
| – | – |
|
|
APLS
103
DELISTED
Apellis Pharmaceuticals
APLS
| $6.54M | 0.23% |
152,538
-63,479
| -29% | -$3M |
|
|
VRNA
104
DELISTED
Verona Pharma
VRNA
| $6.29M | 0.22% |
751,905
| – | – |
|
|
FOLD
105
DELISTED
Amicus Therapeutics
FOLD
| $6.14M | 0.21% |
621,659
+216,033
| +53% | +$3.34M |
|
|
YMAB
106
DELISTED
Y-mAbs Therapeutics
YMAB
| $5.98M | 0.21% |
197,820
+121,272
| +158% | +$4.97M |
|
107
Arvinas
ARVN
$518M
| $5.68M | 0.2% |
85,997
+12,538
| +17% | +$959K |
|
|
TRIL
108
DELISTED
Trillium Therapeutics Inc.
TRIL
| $5.68M | 0.2% |
529,226
-288,558
| -35% | -$3.57M |
|
|
MORF
109
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $5.67M | 0.19% |
+89,559
| New | +$4.11M |
|
|
BCEL
110
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $5.4M | 0.19% |
352,424
| – | – |
|
111
Teladoc Health
TDOC
$1.22B
| $5.39M | 0.19% |
29,664
-26,856
| -48% | -$6.23M |
|
112
Align Technology
ALGN
$12.1B
| $5.38M | 0.18% |
9,925
-116
| -1% | -$64.1K |
|
113
Travere Therapeutics
TVTX
$5.2B
| $5.32M | 0.18% |
+212,869
| New | +$5.88M |
|
|
TCRR
114
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $5.21M | 0.18% |
+235,808
| New | +$6.43M |
|
115
Aurinia Pharmaceuticals
AUPH
$1.91B
| $5.17M | 0.18% |
397,920
+97,309
| +32% | +$1.41M |
|
|
AMED
116
DELISTED
Amedisys
AMED
| $5.14M | 0.18% |
19,395
| – | – |
|
117
Zai Lab
ZLAB
$2.06B
| $5.01M | 0.17% |
37,523
| – | – |
|
118
Healthpeak Properties
DOC
$15.1B
| $4.77M | 0.16% |
150,392
| – | – |
|
119
Revvity
RVTY
$12.6B
| $4.76M | 0.16% |
37,094
| – | – |
|
120
Cogent Biosciences
COGT
$6.65B
| $4.72M | 0.16% |
537,742
| – | – |
|
121
Icon
ICLR
$12.6B
| $4.63M | 0.16% |
+23,592
| New | +$4.66M |
|
122
BridgeBio Pharma
BBIO
$15.7B
| $4.6M | 0.16% |
+74,714
| New | +$4.89M |
|
123
Personalis
PSNL
$1.35B
| $4.42M | 0.15% |
+179,731
| New | +$6.16M |
|
124
Centene
CNC
$30.7B
| $4.3M | 0.15% |
67,290
-16,855
| -20% | -$1.04M |
|
125
Intellia Therapeutics
NTLA
$1.49B
| $4.27M | 0.15% |
+53,180
| New | +$3.57M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Tekla Capital Management held 226 positions worth $2.91B, up 2.1% from $2.85B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Tekla Capital Management's Q1 2021 filing shows 26 new, 31 increased, 48 reduced and 30 closed positions. Its largest new stake was Universal Health Services: 71,323 shares worth $9.51M. The largest sale was Alexion Pharmaceuticals, an estimated $60.5M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.
- Tekla Capital Management's largest Q1 2021 buy was Universal Health Services: 71,323 shares worth $9.51M.
- Tekla Capital Management added most to Elevance Health in Q1 2021, an estimated $41M increase.
- Tekla Capital Management's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $60.5M.
- Tekla Capital Management fully exited NovoCure in Q1 2021, selling an estimated $15.2M.
- Tekla Capital Management's ten largest holdings make up 30% of its $2.91B portfolio in Q1 2021.
- Tekla Capital Management opened 26 new positions and closed 30 in Q1 2021.
- Tekla Capital Management's portfolio value rose 2.1% quarter-over-quarter to $2.91B.
Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.